Goldman Sachs Group Inc Eye Point Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,531,556 shares of EYPT stock, worth $13 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,531,556
Previous 1,531,556
-0.0%
Holding current value
$13 Million
Previous $8.3 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding EYPT
# of Institutions
164Shares Held
71.6MCall Options Held
232KPut Options Held
207K-
Cormorant Asset Management, LP Boston, MA8.33MShares$70.8 Million4.79% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$57.9 Million1.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.2MShares$52.8 Million0.07% of portfolio
-
Franklin Resources Inc San Mateo, CA4.15MShares$35.3 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.09MShares$34.8 Million0.05% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $290M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...